Clinical trials
Phase 4 Neoplasm Metastasis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 10 |
| Unknown status | 7 |
| Recruiting | 6 |
| Not yet recruiting | 3 |
| Withdrawn | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Hoffmann-La Roche | 3 |
| Bayer | 2 |
| Centre Francois Baclesse | 2 |
| Ottawa Hospital Research Institute | 2 |
| Spanish Breast Cancer Research Group | 2 |
| Xu jianmin | 2 |
| Ain Shams Maternity Hospital | 1 |
| American University of Beirut Medical Center | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasm Metastasis | 55 |
| Breast Neoplasms | 12 |
| Colorectal Neoplasms | 7 |
| Melanoma | 5 |
| Prostatic Neoplasms | 5 |
| Neoplasms | 4 |
| Pain | 4 |
| Recurrence | 4 |
| Brain Neoplasms | 3 |
| Carcinoma, Hepatocellular | 3 |
Trials
Showing 26 to 50 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.